Details of the Drug

General Information of Drug (ID: DMUNTE3)

Drug Name

Estradiol

Synonyms

Aerodiol; Alora; Altrad; Aquadiol; Bardiol; Climaderm; Climara; Compudose; Corpagen; Dermestril; Destradiol; Dihydrofolliculin; Dihydromenformon; Dihydrotheelin; Dihydroxyesterin; Dihydroxyestrin; Dihydroxyoestrin; Dimenformon; Diogyn; Diogynets; Divigel; Elestrin; Encore; Esclim; Estrace; Estraderm; Estradiolo; Estradiolum; Estradot; Estraldine; Estrasorb; Estreva; Estrifam; Estring; Estroclim; Estrodiolum; Estrogel; Estrovite; Evamist; Evorel; Extrasorb; Femanest; Femestral; Femestrol; Fempatch; Femtran; Follicyclin; Gelestra; Ginedisc; Ginosedol; GynPolar; Gynergon; Gynestrel; Gynodiol; Gynoestryl; Innofem; Lamdiol; Macrodiol; Macrol; Menest; Menorest; Microdiol; Nordicol; Oesclim; Oestergon; Oestradiol; Oestradiolum; Oestrogel; Oestroglandol; Oestrogynal; Ovahormon; Ovasterol; Ovastevol; Ovociclina; Ovocyclin; Ovocycline; Ovocylin; Perlatanol; Polyestradiol; Primofol; Profoliol; Progynon; Syndiol; Systen; Tradelia; Trocosone; Vagifem; Vivelle; Zerella; Zesteem; Zesteen; Zumenon; Climara Forte; Component of Menrium; Estraderm MX; Estraderm TTS; Estradiolo [DCIT]; Estradiolum [INN]; Estring vaginal ring; Estrofem Forte; Oestradiol Berco; Oestradiol R; Progynon DH; Sandrena Gel; Sisare Gel; Trial SAT; CMC_11154; Compudose 200; Compudose 365; E 2; E 8875; E0025; Epiestriol 50; Estraderm TTS 100; Estraderm TTS 50; Estrapak 50; Estroclim 50; Estrofem 2; Sandrena 1; [3H]]estradiol; Activella (TN); Alora (TN); Alpha-Oestradiol; AngeliQ (TN); B-Estradiol; Beta-Estradiol; Beta-Oestradiol; Beta-estradiol; Cis-Estradiol; Cis-Oestradiol; Climara (TN); D-Estradiol; D-Oestradiol; Divigel (TN); E(sub 2); Elestrin (TN); Estrace (TN); Estraderm (TN); Estraderm TTS (TN); Estradiol [USAN:INN]; Estradiol acetate (TN); Estradiol cypionate (TN); Estradiol valerate (TN); Estradiol-17 beta; Estradiol-17beta; Estrasorb (TN); Estrasorb Topical (TN); Estring (TN); Estrofem (TN); Estrogel (TN); EvaMist (TN); Femring (TN); Innofem (TN); Menostar (TN); Oestradiol-17beta; Progynon-DH; Progynova (TN); S-21400; SK-Estrogens; SL-1100; VIVELLE-DOT; Vagifem (TN); Vivelle (TN); [3H]-estradiol; Estradiol-17-beta; Estradiol-3,17beta; Oestradiol-17-beta; Vivelle-Dot (TN); D-3,17beta-Estradiol; [2,4,6,7-3H]-E2; 17 beta-Estradiol; 17-.BETA.-Estradiol; 17-beta-OH-estradiol; 17-beta-estradiol; 17.beta.-Estradiol; 17.beta.-Oestradiol; 17b-Oestradiol; 17beta oestradiol; 17beta-Estradiol; 17beta-Oestradiol; 3,17-beta-Estradiol; 3,17-beta-Oestradiol; 3,17.beta.-Estradiol; 3,17beta-Estradiol

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[1]
Breast cancer	2C60-2C65	Approved	[2]
Hot flushes	GA30	Approved	[1]
Infertility	GB04	Approved	[1]
Obsolete atrophic vulva	N.A.	Approved	[1]
Metastatic prostate carcinoma	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Estrogens

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

272.4

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance: The clearance of drug is 29.9 +/- 15.5 mL/min/kg [4]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 16.9 +/- 6.0 h [4]
Metabolism: The drug is metabolized via the liver [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.8356 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.016% [7]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.2 L/kg [7]
Water Solubility: The ability of drug to dissolve in water is measured as 0.09 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Blood luteinising hormone increased	Not Available	LHCGR	OTSVIJ6I	[8]
Cytology abnormal	Not Available	CARMIL1	OT1A5IX5	[8]
Cytology abnormal	Not Available	TLN1	OTTD2YXM	[8]
Lipid metabolism disorder	Not Available	HMGCR	OTRT3F3U	[8]
-----------

Chemical Identifiers

Formula: C18H24O2
IUPAC Name: (8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
Canonical SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O
InChI: InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1
InChIKey: VOXZDWNPVJITMN-ZBRFXRBCSA-N

Cross-matching ID

PubChem CID: 5757
ChEBI ID: CHEBI:16469
CAS Number: 17916-67-5
DrugBank ID: DB00783
TTD ID: D08QMX
VARIDT ID: DR00129
INTEDE ID: DR0007
ACDINA ID: D00246

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Agonist	[9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[10]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[12]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[13]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[14]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[15]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[16]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[17]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[18]
Cytochrome P450 1B1 (CYP1B1)	DE9QHP6	CP1B1_HUMAN	Substrate	[14]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[19]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[18]
Sulfotransferase 1A1 (SULT1A1)	DEYWLRK	ST1A1_HUMAN	Substrate	[20]
Thiopurine methyltransferase (TPMT)	DEFQ8VO	TPMT_HUMAN	Substrate	[21]
Lactoperoxidase (LPO)	DEHX1DZ	PERL_HUMAN	Substrate	[22]
Farnesol dehydrogenase (AKR1B15)	DER0XCH	AK1BF_HUMAN	Substrate	[23]
Dehydrogenase/reductase retSDR3 (HSD17B14)	DEGTB1K	DHB14_HUMAN	Substrate	[24]
UDP-glucuronosyltransferase 2B28 (UGT2B28)	DEB7I4M	UDB28_HUMAN	Substrate	[25]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4)	OTQK3M9X	ABHD4_HUMAN	Gene/Protein Processing	[26]
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)	OTG2T749	CP24A_HUMAN	Gene/Protein Processing	[27]
1,4-alpha-glucan-branching enzyme (GBE1)	OTK2N05B	GLGB_HUMAN	Gene/Protein Processing	[28]
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2)	OT5I4Y9K	PLCB_HUMAN	Gene/Protein Processing	[29]
1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon (AGPAT5)	OTNY3VMD	PLCE_HUMAN	Gene/Protein Processing	[26]
1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 (PNPLA3)	OTR4990X	PLPL3_HUMAN	Gene/Protein Processing	[27]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1)	OT9HYT7A	PLCB1_HUMAN	Gene/Protein Processing	[29]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-2 (PLCB2)	OTPAHDGO	PLCB2_HUMAN	Gene/Protein Processing	[26]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1 (PLCD1)	OT6WFVXZ	PLCD1_HUMAN	Gene/Protein Processing	[26]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-3 (PLCD3)	OTB22A4J	PLCD3_HUMAN	Gene/Protein Processing	[30]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Acne vulgaris

ICD Disease Classification

ED80

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Estrogen receptor (ESR)	DTT	ESR1	2.05E-08	-0.08	-0.31
P-glycoprotein 1 (ABCB1)	DTP	P-GP	3.39E-11	-2.93E-01	-6.11E-01
Breast cancer resistance protein (ABCG2)	DTP	BCRP	7.63E-03	-2.10E-01	-2.66E-01
Sulfotransferase 1A1 (SULT1A1)	DME	SULT1A1	4.66E-98	-6.77E-01	-1.73E+00
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	6.50E-01	1.30E-02	5.24E-02
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	9.91E-19	-2.17E-01	-5.99E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	5.68E-18	-1.46E-01	-5.75E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	2.80E-10	1.27E-04	4.77E-04
Lactoperoxidase (LPO)	DME	LPO	1.89E-18	-2.38E-01	-6.98E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	9.91E-02	-6.39E-02	-2.08E-01
Dehydrogenase/reductase retSDR3 (HSD17B14)	DME	HSD17B14	1.37E-13	-1.59E-01	-4.10E-01
Thiopurine methyltransferase (TPMT)	DME	TPMT	1.77E-66	-4.82E-01	-1.14E+00
UDP-glucuronosyltransferase 2B28 (UGT2B28)	DME	UGT2B28	1.88E-18	2.24E-01	6.62E-01
Cytochrome P450 1B1 (CYP1B1)	DME	CYP1B1	3.72E-05	2.34E-01	2.08E-01
Cytochrome P450 1A1 (CYP1A1)	DME	CYP1A1	5.48E-47	-3.01E-01	-8.32E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	7.53E-12	-3.19E-01	-7.75E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	8.54E-05	-6.60E-02	-1.90E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Estradiol

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Lapatinib	DM3BH1Y	Moderate	Decreased clearance of Estradiol due to the transporter inhibition by Lapatinib.	Breast cancer [2C60-2C6Y]	[31]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Estradiol caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[32]
-----------

Coadministration of a Drug Treating the Disease Different from Estradiol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Estradiol caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[33]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Estradiol caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[33]
Dronedarone	DMA8FS5	Moderate	Decreased clearance of Estradiol due to the transporter inhibition by Dronedarone.	Angina pectoris [BA40]	[34]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Estradiol caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[35]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Estradiol caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[36]
Aminophylline	DML2NIB	Moderate	Decreased metabolism of Estradiol caused by Aminophylline.	Asthma [CA23]	[37]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Estradiol caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[38]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Estradiol caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[39]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Estradiol caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[33]
Atorvastatin	DMF28YC	Minor	Decreased metabolism of Estradiol caused by Atorvastatin mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[40]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Estradiol caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[33]
Anisindione	DM2C48U	Moderate	Antagonize the effect of Estradiol when combined with Anisindione.	Coagulation defect [3B10]	[41]
Oxtriphylline	DMLHSE3	Moderate	Decreased metabolism of Estradiol caused by Oxtriphylline.	Cough [MD12]	[37]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Estradiol caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[38]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Estradiol caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[35]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Estradiol due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[42]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Estradiol caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[38]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Estradiol caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[43]
Primidone	DM0WX6I	Moderate	Increased metabolism of Estradiol caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Estradiol caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Estradiol caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Estradiol caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[44]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Estradiol caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Estradiol caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[45]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Estradiol caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Estradiol caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Dantrolene	DM1D8XY	Major	Increased risk of hepatotoxicity by the combination of Estradiol and Dantrolene.	Fever [MG26]	[46]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Estradiol caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[47]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Estradiol caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[36]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Estradiol caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[36]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Estradiol caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[36]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Estradiol caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[33]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Estradiol caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[48]
ABT-450	DMFW860	Major	Decreased metabolism of Estradiol caused by ABT-450 mediated inhibition of UGT.	Hepatitis virus infection [1E50-1E51]	[49]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Estradiol caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[50]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Estradiol caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[35]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Estradiol caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[33]
Tipranavir	DM8HJX6	Moderate	Increased risk of skin rash by the combination of Estradiol and Tipranavir.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Estradiol caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[52]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Estradiol caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Estradiol caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[54]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Estradiol caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[55]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Estradiol caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[35]
Melatonin	DMKWFBT	Minor	Decreased metabolism of Estradiol caused by Melatonin mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[38]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Estradiol caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[45]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Estradiol caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[56]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Estradiol caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[33]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Estradiol caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[45]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Estradiol caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[57]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Estradiol caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[33]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Estradiol caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[35]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Estradiol caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[58]
Carfilzomib	DM48K0X	Major	Additive thrombogenic effects by the combination of Estradiol and Carfilzomib.	Multiple myeloma [2A83]	[38]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Estradiol caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[45]
Nilotinib	DM7HXWT	Moderate	Decreased clearance of Estradiol due to the transporter inhibition by Nilotinib.	Myeloproliferative neoplasm [2A20]	[59]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Estradiol caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[60]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Estradiol caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[61]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Estradiol caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[62]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Estradiol caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[63]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Estradiol caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[64]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Estradiol caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[33]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Estradiol and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[65]
Fentanyl	DM8WAHT	Minor	Increased plasma concentrations of Estradiol and Fentanyl due to competitive inhibition of the same metabolic pathway.	Sensation disturbance [MB40]	[38]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Estradiol caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[66]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Estradiol caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[45]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Estradiol caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[38]
Armodafinil	DMGB035	Minor	Increased metabolism of Estradiol caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[67]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Estradiol due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[68]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Estradiol and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[65]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Estradiol and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[65]
-----------


⏷ Show the Full List of 70 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 27	E00381	83511	Colorant
D&C red no. 30	E00456	3000709	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Hydrazine yellow	E00409	164825	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Vanillin	E00049	1183	Flavoring agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Crospovidone	E00626	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Estradiol 1.25 mg tablet	1.25 mg	Oral Tablet	Oral
Estradiol 0.3 mg tablet	0.3 mg	Oral Tablet	Oral
Estradiol 0.625 mg tablet	0.625 mg	Oral Tablet	Oral
Estradiol 1 mg tablet	1 mg	Oral Tablet	Oral
Estradiol 2 mg tablet	2 mg	Oral Tablet	Oral
Estradiol 0.5 mg tablet	0.5 mg	Oral Tablet	Oral
Estradiol 0.01 mg tablet	0.01 mg	Vaginal Tablet	Vaginal

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Estradiol FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1013).
3	BDDCS applied to over 900 drugs
4	Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol. 1995 Sep;35(9S):18S-24S. doi: 10.1002/j.1552-4604.1995.tb04143.x.
5	Tubic-Grozdanis M, Hilfinger JM, Amidon GL, Kim JS, Kijek P, Staubach P, Langguth P: Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm Res. 2008 Jul;25(7):1591-600. doi: 10.1007/s11095-007-9519-6. Epub 2008 Jan 24.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9	Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201.
10	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
11	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
12	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
13	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
14	Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
15	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
16	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
17	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
18	Drug Interactions Flockhart Table
19	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
20	Proposed role of the sulfotransferase/sulfatase pathway in modulating yolk steroid effects. Integr Comp Biol. 2008 Sep;48(3):419-27.
21	Influence of estradiol-17 beta and progesterone on catechol-O-methyltransferase and monoamine oxidase activities in uterine artery and myometrium of ovariectomized pigs. Arch Vet Pol. 1993;33(1-2):29-37.
22	The metabolism of 17 beta-estradiol by lactoperoxidase: a possible source of oxidative stress in breast cancer. Carcinogenesis. 1994 Nov;15(11):2637-43.
23	Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates. J Biol Chem. 2015 Mar 6;290(10):6531-45.
24	Expression patterns of 17beta-hydroxysteroid dehydrogenase 14 in human tissues. Horm Metab Res. 2012 Dec;44(13):949-56.
25	Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry. 2001 Apr 3;40(13):3869-81.
26	17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
27	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
28	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
29	Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
30	Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2011 Feb;123(3-5):140-50.
31	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
32	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
33	Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
34	Product Information. Ambien (zolpidem). sanofi-aventis, Bridgewater, NJ.
35	Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
36	Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9. [PMID: 2547410]
37	Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R "Effects of tobacco smoking and oral contraceptive use on theophylline disposition." Br J Clin Pharmacol 16 (1983): 271-80. [PMID: 6626419]
38	Cerner Multum, Inc. "Australian Product Information.".
39	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
40	Product Information. Lipitor (atorvastatin). Parke-Davis, Morris Plains, NJ.
41	Notelovitz M "Oral contraception and coagulation." Clin Obstet Gynecol 28 (1985): 73-83. [PMID: 3987135]
42	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
43	Adson DE, Kotlyar M "A probable interaction between a very low-dose oral contraceptive and the antidepressant nefazodone: a case report." J Clin Psychopharmacol 21 (2001): 618-9. [PMID: 11763013]
44	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
45	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
46	Product Information. Dantrium (dantrolene). Procter and Gamble Pharmaceutic, Cincinnati, OH.
47	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
48	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
49	Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
50	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
51	Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
52	Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
53	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
54	Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
55	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
56	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
57	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
58	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
59	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
60	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
61	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
62	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
63	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
64	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
65	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
66	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
67	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
68	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.